Results 151 to 160 of about 3,103 (172)

Elexacaftor/ivacaftor/tezacaftor

Reactions Weekly, 2022
  +8 more sources

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Lancet, The, 2019
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people ...
Harry Heijerman, Edward F Mckone, Damian G Downey   +2 more
exaly   +3 more sources

Elexacaftor/ivacaftor/tezacaftor

Reactions Weekly, 2021
  +5 more sources

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial

American Journal of Respiratory and Critical Care Medicine, 2022
David P Nichols, Sonya L Heltshe, Scott H Donaldson   +2 more
exaly  

Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

American Journal of Respiratory and Critical Care Medicine, 2021
Dominique Grenet, Julie Macey, Lydie Lemonnier   +2 more
exaly  

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

American Journal of Respiratory and Critical Care Medicine, 2021
Edith T Zemanick, Jane C Davies, Ronald L․ Gibson   +2 more
exaly  

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles

American Journal of Respiratory and Critical Care Medicine, 2022
Simon Y Graeber, Lutz Naehrlich, M Stahl   +2 more
exaly  

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

American Journal of Respiratory and Critical Care Medicine, 2022
Marcus A Mall, Silvia Gärtner, Alexander Moeller   +2 more
exaly  

Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers

Pediatric Pulmonology, 2023
Christina J Bathgate, Emily F Muther, Anna M Georgiopoulos   +2 more
exaly  

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles

American Journal of Respiratory and Critical Care Medicine, 2022
Simon Y Graeber, M Stahl, Martha Dohna
exaly